Medicinal Fungi Evidence Update

Status and design: accepted peer-reviewed Frontiers clinical-trial article; final formatted full text is pending. The corresponding April preprint and registry provide the detailed methods. Remote, randomised, double-blind, placebo-controlled, eight-week trial in adults aged 40-75 with self-reported mild-to-moderate cognitive difficulty.

Population and analysis: 150 were randomised; 120 completed; 109 were analysed (57 active, 52 placebo). The gap between randomised and analysed participants is substantial. The registry was first posted on 25 March 2025, after the 21 February study start, and describes an observational, one-treatment-group study even though the article reports a two-arm RCT.

Outcomes: the Juggle Factor task improved more over time with the product (p=0.001; +0.45 z-score), but no individual timepoint separated significantly. Memory Grid, Target Tracker, Mental Map, Sandia's Matrices and the composite cognitive score were null. Subjective sleep quality, morning restedness and mood improved faster; placebo improved motivation faster. No adverse events occurred in the active arm.

Interpretation and bias: one task-specific signal amid several null tests does not establish broad cognitive enhancement. The registry names a composite attention/short-term/working-memory outcome, while the paper foregrounds one component despite the null composite. M2 Ingredients funded the study, supplied the product and employed two authors; sponsor authors reviewed the manuscript.

Status and design: peer-reviewed, published 20 October and identified after the previous brief. Randomised, double-blind, placebo-controlled, three-arm trial in 84 women aged 18-26 who felt stressed and/or anxious but had no diagnosed psychiatric disorder. Arms were placebo n=28, blend n=27 and lion's mane n=29; treatment lasted 28 days with a Day-42 follow-up.

Primary outcome: the blend produced lower GAD-7 anxiety than lion's mane overall (p=0.018) and on Day 28 (p=0.003). The article reports no significant blend-versus-placebo contrast for the primary outcome. Thus it does not establish placebo-controlled anxiolytic efficacy. Lion's mane alone showed no advantage.

Secondary and null findings: HADS anxiety and perceived-stress interactions did not survive false-discovery-rate correction (q=0.072). Stress VAS, fatigue and self-esteem showed no treatment effect. All groups improved substantially across every psychological measure, consistent with participation, expectancy or repeated-assessment effects. Adverse-event frequency did not differ; 50 events occurred in 31 participants, with one placebo withdrawal.

Quality and bias: good blinding and 96.7% capsule-count compliance. However, recruitment stopped at 84 versus a 135 target; baseline fruit/vegetable intake, waist-to-hip ratio and stress VAS differed; the active arms contained unequal lion's-mane doses; and no Reishi-only arm can separate Reishi from mixture or dose effects. Northumbria funded the study internally; Sempera Organics supplied products and was reported to have no research role; authors declared no conflicts.

No new systematic review or meta-analysis met the inclusion threshold. A 23 October narrative review of Cordyceps taxonomy, metabolites and production usefully emphasises species authentication, product standardisation, pharmacokinetic uncertainty and inadequate clinical validation, but supplies no pooled clinical estimate and should not change an evidence grade.

No newly published preclinical study cleared the high-quality threshold this week.

This peer-reviewed 27 October mouse paper reported improvements in metabolic measures, Y-maze alternation, barrier proteins and hippocampal inflammatory/neurochemical markers.

Overall group sizes and blinding are not stated; selected analyses used six mice per group and western blots used three biological samples. Microbiome changes are associative: there was no transfer, depletion or pathway-blockade experiment. Public Chinese grants funded the work and no commercial conflicts were declared.